TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20390667

Group type: EXPERIMENTAL
Intervention: Health consequence message frame
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Secondhand smoke message frame
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Industry manipulation message frame
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 315
Study: 17938887

Group type: EXPERIMENTAL
Intervention: Heparinized solution (1 IU/ml)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Heparinized solution
Number of subjects: 133
Study: 17053959

Group type: EXPERIMENTAL
Intervention: Furosemide-induced natriuresis test
Number of subjects: 15

Group type: COMPARATOR
Intervention: Volume expansion with saline and intravenous infusion of octreotide
Number of subjects: 15
Study: 12754273

Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli 0113, 2 ng/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 11063956

Group type: EXPERIMENTAL
Intervention: Dietary counseling by a registered dietitian
Number of subjects: 136

Group type: COMPARATOR
Intervention: Dietary counseling by a physician only
Number of subjects: 136
Study: 9042265

Group type: EXPERIMENTAL
Intervention: Serum alpha-beta A immunoreactive inhibin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CA125
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 39
Study: 7538658

Group type: EXPERIMENTAL
Intervention: Lenograstim (5, 10, or 20 microgram/kg/day SC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lenograstim (5 microgram/kg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lenograstim (2 microgram/kg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lenograstim (twice daily on alternate days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lenograstim therapy
Number of subjects: 12
Study: 3262980

Group type: EXPERIMENTAL
Intervention: Addition of 1 ml of lignocaine (10 mg) to 19 ml of propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isotonic saline added to 19 ml of propofol
Number of subjects: 80
Study: 30969323

Group type: EXPERIMENTAL
Intervention: Visit-to-visit systolic blood pressure variability (BPV)
Number of subjects: 3912

Group type: EXPERIMENTAL
Intervention: Visit-to-visit diastolic blood pressure variability (BPV)
Number of subjects: 3912

Group type: EXPERIMENTAL
Intervention: Visit-to-visit pulse pressure variability (BPV)
Number of subjects: 3912

Group type: EXPERIMENTAL
Intervention: Cumulative major adverse cardiovascular events
Number of subjects: 3912
Study: 29197404

Group type: EXPERIMENTAL
Intervention: IBBIS mental health care integrated with IBBIS vocational rehabilitation
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: IBBIS mental health care and standard vocational rehabilitation
Number of subjects: 603

Group type: COMPARATOR
Intervention: Standard mental health care and standard vocational rehabilitation
Number of subjects: 603
Study: 25868100

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 23432777

Group type: EXPERIMENTAL
Intervention: Polylactic acid (PLA)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Polyacrylamide hydrogel (PH)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Both PLA and PH
Number of subjects: 148
Study: 21424272

Group type: EXPERIMENTAL
Intervention: Treatment supporter intervention (TS arm)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard adherence intervention package (non-TS arm)
Number of subjects: 174
Study: 19200542

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 270
Study: 18074034

Group type: EXPERIMENTAL
Intervention: AS+SP+PQ
Number of subjects: 104

Group type: COMPARATOR
Intervention: AS+SP
Number of subjects: 104
Study: 15450786

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 14
Study: 11439383

Group type: EXPERIMENTAL
Intervention: EHTS subjects
Number of subjects: 30
Study: 9682999

Group type: EXPERIMENTAL
Intervention: Amisulpride (ASP) 1000 mg/day (mean daily dose: 956 mg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Flupentixol (FPX) 25 mg/day (mean daily dose: 22.6 mg)
Number of subjects: 132
Study: 8562296

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril or enalapril)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (non-ACE inhibitors)
Number of subjects: 191
Study: 2108187

Group type: EXPERIMENTAL
Intervention: GHRP 0.1 microgram/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRP 0.3 microgram/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRP 1.0 microgram/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: GHRH 1.0 microgram/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRP 0.1 and 0.3 microgram/kg plus GHRH 1.0 microgram/kg
Number of subjects: 18
Study: 120757

Group type: EXPERIMENTAL
Intervention: Sodium valproate (maximum tolerated doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study: 30842065

Group type: EXPERIMENTAL
Intervention: Endogenous testosterone genetically predicted by variants in the JMJD1C gene region
Number of subjects: 3225

Group type: EXPERIMENTAL
Intervention: Genetically predicted testosterone based on JMJD1C gene region variants
Number of subjects: 3225

Group type: EXPERIMENTAL
Intervention: Testosterone genetically predicted by potentially pleiotropic variants in the SHBG gene region
Number of subjects: 3225
Study: 28385352

Group type: EXPERIMENTAL
Intervention: MLE4901 (40 mg, orally, twice daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (orally, twice daily)
Number of subjects: 37
Study: 26275583

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 10
Study: 24083696

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Ringer's solution)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both ANH and Control groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ANH group
Number of subjects: 30
Study: 21504872

Group type: EXPERIMENTAL
Intervention: MIDonline intervention (n = 110)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (n = 92)
Number of subjects: 202
Study: 17916806

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate 50/500 microg twice daily
Number of subjects: 1323

Group type: COMPARATOR
Intervention: tiotropium 18 microg once daily
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate
Number of subjects: 1323

Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 1323
Study: 17070150

Group type: EXPERIMENTAL
Intervention: Dexamethasone-eluting stents
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (unloaded stents)
Number of subjects: 92
Study: 12835986

Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium (5 micromol/kg)
Number of subjects: 923
Study: 10958384

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1923169

Group type: EXPERIMENTAL
Intervention: Outlet forceps delivery
Number of subjects: 333

Group type: COMPARATOR
Intervention: Spontaneous vaginal delivery
Number of subjects: 333
Study: 7163513

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no oxytocin infusion)
Number of subjects: 0
Study: 30599808

Group type: EXPERIMENTAL
Intervention: Plantarflexor EMG during standing balance challenges
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Increasing challenge to standing balance
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study: 29806782

Group type: EXPERIMENTAL
Intervention: Unpredictable sound exposure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Predictable sound exposure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 30
Study: 27114421

Group type: EXPERIMENTAL
Intervention: Sequential Therapy (ST) for 10 days
Number of subjects: 601

Group type: COMPARATOR
Intervention: Triple Therapy (TT) for 7 days
Number of subjects: 601
Study: 25270152

Group type: EXPERIMENTAL
Intervention: Rituximab as induction therapy after renal transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23147050

Group type: EXPERIMENTAL
Intervention: Aerobic physical training program (PTP) on a treadmill, three times a week, for six weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no aerobic physical training program)
Number of subjects: 36
Study: 20200306

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Baseline A1C levels
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Baseline blinded CGM
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Age and insulin modality (pump vs multiple daily injections)
Number of subjects: 176
Study: 17608776

Group type: EXPERIMENTAL
Intervention: Octreotide (200 mug)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16808313

Group type: EXPERIMENTAL
Intervention: Pentaerythritol compositum (20 mg of pentaerythritol tetranitrate and 0.5 mg of nitroglycerine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroglycerine (0.5 mg)
Number of subjects: 20
Study: 12011664

Group type: EXPERIMENTAL
Intervention: ASA 75 mg daily
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study: 10048059

Group type: EXPERIMENTAL
Intervention: Ultrasound microneurosurgical unit
Number of subjects: 299
Study: 7600846

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous coronary interventions (PTCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Directional atherectomy and stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elective stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser and rotational atherectomy
Number of subjects: 0
Study: 2407227

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion with doxorubicin hydrochloride (Adriamycin) 30 mg every 24 hours for 3 days, followed by irradiation (30 or 35 Gy in 10 fractions or 46 Gy in 23 to 25 fractions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 60
Study: 6407638

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 100
Study: 31390637

Group type: COMPARATOR
Intervention: Adapted reference values using the LMS method after instrumental dead space reduction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard lung function equipment adaptation
Number of subjects: 40
Study: 30410653

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27966318

Group type: EXPERIMENTAL
Intervention: Levofloxacin administration after EMR (Group B)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ceftazidime administration after EMR (Group C)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No antibiotics treatment after EMR (Group A)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 115
Study: 25730927

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low-frequency magnetic therapy
Number of subjects: 92
Study: 23645068

Group type: EXPERIMENTAL
Intervention: Gynocular
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard colposcope
Number of subjects: 69

Group type: COMPARATOR
Intervention: Pap smear
Number of subjects: 69

Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 69
Study: 20516755

Group type: EXPERIMENTAL
Intervention: Postoperative cognitive dysfunction assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative delirium monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine cognitive function assessment
Number of subjects: 0
Study: 19083689

Group type: EXPERIMENTAL
Intervention: MET with 30‐s post‐isometric stretch phase
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MET with 3‐s post‐isometric stretch phase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 40
Study: 15721091

Group type: EXPERIMENTAL
Intervention: Bucindolol therapy
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Suspected nonfatal MI cohort
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Control group (no suspected nonfatal MI)
Number of subjects: 2708
Study: 12666516

Group type: EXPERIMENTAL
Intervention: Joint consultations by general practitioners and rheumatologists
Number of subjects: 166

Group type: COMPARATOR
Intervention: Regular referral to the Rheumatology outpatients' clinic
Number of subjects: 166
Study: 10535346

Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone orally followed by gemeprost 1 mg vaginally 24 hours later
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone orally followed by gemeprost 1 mg vaginally 48 hours later
Number of subjects: 64
Study: 8690200

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1654983

Group type: COMPARATOR
Intervention: As required (AR) chemotherapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Planned chemotherapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: As required (AR) chemotherapy with treatment-free interval (TFI) greater than 8 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: As required (AR) chemotherapy with treatment-free interval (TFI) less than 4 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Quality of life assessment for AR patients
Number of subjects: 300
Study: 6896672

Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linoleic acid (from lecithin and safflower oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30775818

Group type: EXPERIMENTAL
Intervention: Aquatic motor intervention (Ai Chi), 14 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: On-land motor intervention (Tai Chi), 14 weeks
Number of subjects: 41
Study: 30235385

Group type: EXPERIMENTAL
Intervention: Novel two-part skincare system (LVS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26598747

Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg orally twice daily
Number of subjects: 138
Study: 24339179

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, followed by either CZP 200 mg every 2 weeks or CZP 400 mg every 4 weeks
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg every 2 weeks or CZP 400 mg every 4 weeks
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 22903484

Group type: EXPERIMENTAL
Intervention: Castor oil before imaging and fasting after midnight (group 1)
Number of subjects: 186

Group type: COMPARATOR
Intervention: No bowel preparation and allowed to eat and drink before examination (group 2)
Number of subjects: 186
Study: 19189371

Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC)
Number of subjects: 463

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 463
Study: 17264183

Group type: EXPERIMENTAL
Intervention: Vitamin D with calcium supplementation
Number of subjects: 45492

Group type: COMPARATOR
Intervention: Vitamin D alone
Number of subjects: 45492

Group type: EXPERIMENTAL
Intervention: Vitamin D with calcium vs. Vitamin D alone
Number of subjects: 45492
Study: 15260469

Group type: EXPERIMENTAL
Intervention: Inspiratory flow at 20 L/min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inspiratory flow at 60 L/min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Constant inspiratory flow
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Short-term comparative individual studies
Number of subjects: 25
Study: 11584035

Group type: EXPERIMENTAL
Intervention: Choice Stepping Reaction Time (CSRT) test
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: CSRT test
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests (Part B of the Trail Making Test)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Quadriceps strength, simple reaction time, sway with eyes open on a compliant surface, and maximal balance range
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Visual contrast sensitivity and lower limb proprioception
Number of subjects: 477
Study: 9688295

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) in combination with ifosfamide (IFO) and vinorelbine (VNB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ifosfamide (IFO) and vinorelbine (VNB) plus G-CSF
Number of subjects: 20
Study: 8075441

Group type: EXPERIMENTAL
Intervention: 0.3% podophyllotoxin cream
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 2681015

Group type: EXPERIMENTAL
Intervention: Routine ultrasound scanning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluative surveys
Number of subjects: 0
Study: 782964

Group type: EXPERIMENTAL
Intervention: H3N2 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HEqN2 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo vaccine (vaccine diluent)
Number of subjects: 0
Study: 31970507

Group type: EXPERIMENTAL
Intervention: Anteromedial OA (AMOA)
Number of subjects: 472
Study: 31612398

Group type: EXPERIMENTAL
Intervention: USG II/IHN plus GFN block (Group G)
Number of subjects: 54

Group type: COMPARATOR
Intervention: USG II/IHN block alone (Group I)
Number of subjects: 54
Study: 28270128

Group type: EXPERIMENTAL
Intervention: Referral templates for new referrals in four clinical areas (dyspepsia, suspected colorectal cancer, chest pain, confirmed or suspected chronic obstructive pulmonary disease)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Referral templates
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard referral practice
Number of subjects: 500
Study: 26577960

Group type: EXPERIMENTAL
Intervention: Conventional GIC with acid etching (Group CIE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional GIC without acid etching (Group CIN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resin modified GIC with acid etching (Group RMN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resin modified GIC without acid etching (Group RME)
Number of subjects: 40
Study: 23811381

Group type: EXPERIMENTAL
Intervention: Laparoscopic training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Robotic training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall skills improvement
Number of subjects: 16
Study: 21257841

Group type: EXPERIMENTAL
Intervention: Anatomic allograft
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified Weaver-Dunn
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anatomic suture
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nonanatomic allograft
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GraftRope
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 19228800

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (HT) - three strategies: (i) monthly telephone contact; (ii) monthly telephone contact plus weekly transmission of vital signs; (iii) strategy 2 plus monthly 24 h recording of cardiorespiratory activity
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (HT)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Usual outpatient care (control)
Number of subjects: 461
Study: 15882713

Group type: EXPERIMENTAL
Intervention: Routine double-J silicone ureteral stent (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No stent (Group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 14645935

Group type: EXPERIMENTAL
Intervention: Active nicotine patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (standard counselling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined patch groups (active + placebo)
Number of subjects: 0
Study: 10847315

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study: 8774165

Group type: EXPERIMENTAL
Intervention: B mode ultrasonography in Takayasu's arteritis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 16
Study: 1466869

Group type: EXPERIMENTAL
Intervention: Continuous intrathecal baclofen infusion
Number of subjects: 10
Study: 3882364

Group type: EXPERIMENTAL
Intervention: Metronidazole (M)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (C)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Metronidazole and Cotrimoxazole (C plus M)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 72
Study: 31059495

Group type: EXPERIMENTAL
Intervention: Biannual mass drug administration (MDA) with praziquantel alone
Number of subjects: 22500
Study: 29625469

Group type: EXPERIMENTAL
Intervention: Blue light stimulation (1.4, 7.1, 14.3, 28.6, 42.9, 57.1, 71.4 cd/m2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Binocular viewing
Number of subjects: 11

Group type: COMPARATOR
Intervention: Red light stimulation (1.5, 19.1, 38.2, 57.3, 76.3, 152.7, 305.3 cd/m2)
Number of subjects: 11